-
Home
- About PMI
-
Smoke-free approach
- What is harm reduction?
- Absence of combustion
- Nicotine
- The role of smoke-free products
- Tar
- Tobacco Regulation
Smoke-free approachOffering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies.Read More -
Research
- Our Scientific Approach
- Our Findings
- PMI Publications Library
- Literature Reviews
- Independent Studies
- Investigator Initiated Studies (IIS)
- Latest PMI Science Booklet
- Facts and figures on our smoke-free future
ResearchPMI is committed to sharing results as the development and scientific assessment of smoke-free products advance.Read More -
Our Products
- Tobacco Heating System
- Oven Heating System
- MESH Vaping System
- Disposable Vaping System
- Oral Nicotine Pouches
- Nicotine salts product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update Magazine
- Open Science Events
- News
- Conferences Calendar
- Media Library
News & EventsRead our most recent articles and catch up on our latest events and conference presentations.Read More - Contact Us
16th AD/PD Conference 2022
By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now joint into an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders. A central theme of the 2022 conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.